Advances in Endocrine Therapies 2005
Novel treatments targets & therapeutic potential
19th and 20th January 2005 - Workshop 18th January 2005
Kensington Marriott Hotel, London
**** CONFERENCE BROCHURE AVAILABLE NOW - REQUEST YOURS TODAY ****
In such a wide reaching industry, it is important to focus on key areas of
progression. At this conference delegates will learn about new developments
in significant areas of the market, from diabetes and obesity to cancer and
hormone replacement therapies.
THEMES WILL INCLUDE:
**New developments in diabetes - how can your company enter this rapidly
growing & changing market?
**Learn about new approaches to weight loss & emerging therapies for
metabolic diseases
**Advice on how your company can become an industry leader in the market for
infertility drugs
**Improve your clinical trials for osteoporosis & learn about the
alternatives to HRT
**Achieve more efficient insulin delivery - optimise your potential success
**Benefit from the best practice case studies: Forteo; Passport;
Somatostatin
KEY SPEAKERS
**Dr. Anthony Beardsworth, Lead Physician, Primary Care, Eli Lilly
**Dr. Monique Berwaer, Head, Metabolic Diseases, Johnson & Johnson
**Caroline Turnbull, Armidex Brand Leader, AstraZeneca
**Dr. Desmond Thompson, Senior Scientific Director, Merck
**Dr. Milan Zdravkovic, International Medical Officer, NovoNordisk
**Dr. Manfred Ganz, Director, Head of Medical Assessment Strategy and
Business Development, Roche
**Dr. Bharat Tewarie, Executive Vice President, Reproductive Health, Serono
**Dr. Eric Tomlinson, Chief Executive Officer, Altea Therapeutics
**Dr. George Merriam, Scientific Advisor, Theratechnologies
**Dr. Gerald Bernstein, Vice President, Medical Affairs, Generex
Biotechnology
**Dr. Alan Davis, European Medical Director, Kendle
------------------
WHO SHOULD ATTEND
------------------
**Vice President, Global Medical Endocrinology
**Senior Vice President, Endocrine Business
**Senior Medical Director, Endocrinology
**Director, Endocrinology & Metabolism
**Senior Director, Metabolic Diseases
**Global Head, Diabetes & Clinical Research
**Vice President, Diabetes
**Vice President, Glucose Monitoring Systems
**Vice President, Cardiovascular & Metabolism
**Executive Vice President, Women's Health
**Vice President, Reproductive Health
==================================================================
This event will also feature: Pre-conference Interactive Workshop
==================================================================
Glucose Sensing & Insulin Pumps
Workshop leaders: Ian Tilly, Glucose Sensor Specialist, Medtronic MiniMed Uk
& Ireland
Susan Judge, Diabetes Specialist, Nurse & Education
Co-ordinator.
Strategies for pricing and market access of innovative endocrine therapies
Led by: Christian Schuler, Director Health Sciences Division, Simon-Kucher &
Partners
---------------------
DELEGATE REGISTRATION
---------------------
Places at this event are strictly limited so BOOK YOUR PLACE NOW.
To make a booking on this event, please contact me via phone or email. Book
early to secure a place.
- PRICING -
Attend the:
2 Day conference with interactive workshop - ONLY GBP1600 plus VAT
2 Day conference - ONLY GBP1299 plus VAT
Workshop only - ONLY GBP650 plus VAT
- BOOKINGS -
Booking is easy, simply contact me:
Joe Stone
Account Manager - Conference Division
Visiongain B2B Conferences
Tel. +44(0)20 8767 6711
Fax. +44(0)20 8767 5001
mailto:joe.stone@visiongain.com
B2B Conferences is part of the Visiongain Group
**** FULL CONFERENCE AGENDA BELOW ****
===================================
PRE-CONFERENCE INTERACTIVE WORKSHOP
Tuesday 18th January 2005
===================================
Glucose sensing & insulin pumps:
optimise diabetes care & analyse pump therapy
Led by: Ian Tilly, Glucose Sensor Specialist & Susan Judge,
Diabetes Specialist, Nurse & Education Co-ordinator,
Medronic MiniMed UK & Ireland
Main topics of discussion:
. Validation of new treatment efficacy in improving
glycaemic control.
. Enhancing the value of clinical trials.
. Features and benefits of insulin pump therapy.
. Combining sensors & pumps - creating an artificial
pancreas.
Strategies for pricing and market access of innovative endocrine therapies
Led by: Christian Schuler, Director Health Sciences Division, Simon-Kucher &
Partners
Strategies for Pricing and Market Access of Innovative
Endocrine Therapies
. Challenges within the endocrine market environment
. P&R Environment for innovative endocrine therapies
. Key learnings from recent product launches
. The concept of value based pricing
. Pricing techniques
===================================
Day One Wednesday 19th January 2005
===================================
09:00 Registration and coffee
09:30 Opening remarks from the chair
09:40 An Overview of the Industry
Dr. Ray Scraggs, Head Consultant at visiongain, will introduce
questionnaires which give you the chance to make comments
on the Endocrine Industry. The findings will be discussed at
the end of the day in a panel session.
NEW DEVELOPMENTS IN DIABETES
09:50 The Future of the Diabetes Market: What are the
Possibilities for Your Company?
. How to rise to the challenge for advanced and effective treatment
. Impaired metabolism: how to cope with complications
. Tactics for novel target discovery
. Strategies for genomics based drug discovery
. Tips on improving diabetes care - decrease complications and gain
metabolic control
. How to avoid microvascular complications
. Different approaches to post infection therapies
Dr. Manfred Ganz, Director, Head of Medical Assessment Strategy and
Business Development Global Diabetes Care
Roche Diagnostics GmbH
10:30 CASE STUDY: 11 bHSD1 - A Novel Target in the treatment of
Diabetes & Metablic Symdrome
. The potential of selective 11 bHSD1 inhibition in the treatment of
diabetes and associated complications
. The need for a better understanding of the endocrine function of
adipose tissue
. Cortisol induced insulin resistance in man
. HSD1 and metabolic syndrome: what are the possibilities for your
company?
. Effect of selective HSD1 inhibition in diabetic rodents: analysis of
results
. The importance of 11beta-HSD1 in the development of metabolic
syndrome - examination of data from studies of obese rodents
Dr. Monique Berwaer, Head, Metabolic Diseases
Johnson & Johnson
11:10 Morning Coffee
11:30 CASE STUDY: Incretin Mimetics - GLP-1 and Liraglutide
. Mechanism of action: increasing insulin secretion; reducing
glucagon production; delaying gastric emptying
. What are the potential applications?
. Possible multiple benefits including weight loss vs drawbacks of
delivery by injection
. Analysis of results of preclinical testing
. Potential for sustained action - improving patient care
Dr. Milan Zdravkovic, International Medical Officer
Novo Nordisk
12:10 Innovations in Insulin Delivery: Possibilities for New
Technologies
. What will be the future of the insulin pill? - replacing first phase
insulin response
. Recent advances in insulin pump therapy - analysis of new
possibilities & assessment of options
. The impact of oral insulin spray on the market
. Updates on FDA approval for inhaled insulin: overcoming long
term effects
Dr. Gerald Bernstein, Vice President, Medical Affairs
Generex Biotechnology
12:50 Lunch
14:00 CASE STUDY: Passport - The Potential for Transdermal Insulin
Delivery
. Mechanism of action: a sonic applicator deploying
. ultrasound & introducing drug molecules through the skin
Added benefits of combined skin patch and insulin pill
. Increasing administration length: new development of a 24 hour
patch
. Advantages over alternatives - achieve steady and accurate
delivery of your diabetes drugs
. Improve patient compliance - a non-invasive, pain and hassle free
treatment
. Market potential - a cost-effective, efficient treatment without
troublesome side-effects
Dr. Eric Tomlinson, Chief Executive Officer
Altea Therapeutics
NOVEL TREATMENTS IN THE OBESITY MARKET
14:40 New Approaches to Weight Loss Drugs: Responding to Gaps
in the Obesity Market
. Current drugs and their limitations: lessons to be learnt from the
past
. How can body weight be regulated and modified?
. New approaches for discovering novel targets for the treatment of
obesity
Jon Arch, Professorial Research Fellow, Deputy Director of Metabolic
Research
University of Buckingham
15:20 Afternoon Tea
THE ENDOCRINE TREATMENT OF BREAST CANCER
15:40 CASE STUDY: Armidex - the Future of Treatment &
Prevention of Breast Cancer
. The first aromatase inhibitor to be approved - effect on your
market
. Current market for breast cancer drugs - where can you capture a
share?
. Developments in endocrine agents: steps towards the goal of
breast cancer prevention
. Comparison of aromatase inhibitors with tamoxifen - how long
before tamoxifen is obsolete?
. Analysis of results of recent clinical studies
Caroline Turnbull, Arimidex Brand Leader
AstraZeneca
16:20 Questions and Discussion
16:30 Summation of day one from conference chair
16:40 Close of Day One
==================================
Day Two Thursday 20th January 2005
==================================
08:30 Registration and Coffee
09:00 Opening remarks from the Chair
DEVELOPMENTS IN GROWTH HORMONE THERAPIES
09:10 KEYNOTE SESSION
MINI SYMPOSIUM: GROWTH HORMONECLINICAL INSIGHTS & MECHANISMS
With invited manufacturers of growth hormone and growth
hormone secretagogues
Led By: Dr. George Merriam
Scientific Advisor, Professor of Medicine
Theratechnologies, University of Washington
10:10 CASE STUDY: Somatostatin - Developments in the Treatment
of Acromegaly
. Mechanism of action of somatostatin analogues
. The need to improve clinical management of patients
. Addressing patient issues: appropriate dosing regimes & extended
duration preparations
. Defining the role of somatostatin analogues: checking & balancing
hormones & growth
. Advantages of multiple benefits: treating adverse clinical effects
of acromegaly
. SOM230: a new multiligand somatoststatin analogue - the
possibilities for future treatments
Dr. Herbert Schmid, Senior Research Investigator for Somatostatin Research
Novartis
10:50 Morning Coffee
ENDOCRINOLOGY AND WOMEN'S HEALTH ISSUES
11:10 The Endocrinology Of Ageing
. Ageing - the major driver in the endocrine industry: gain your share
of the market
. The underlying mechanisms responsible for reduction in strength,
frequency and production of hormones
. Future targets for age-related diseases: what are the opportunities
for your company?
Dr. Desmond Thompson, Senior Scientific Director
Merck
11:50 Delivering Clinical Trials for Osteoporosis: Improve your
Company's Studies
. Clinical trial metrics & management: ensure your osteoporosis trials
are efficient & cost effective
. Tips for long & short term studies
. Advice on recruiting & retaining trial subjects
. How to select appropriate clinical endpoints for your osteoporosis
trials
. Safety assessments & regulatory requirements: how do they affect
your studies?
Dr. Alan Davies, European Medical Director
Kendle
12:30 Lunch
14:00 CASE STUDY: Forteo - The First Bone Formation Agent in the
Treatment of Osteoporosis
. Mechanism of action: the use of recombinant human parathyroid
hormone: the potential to replace depleted bone stores
. Multiple benefits: forming new bone, increasing bone density
and improving bone strength
. Overcoming possible side effects - what can be done to improve
patient care?
. The proven success of Forteo: results from the fracture
prevention trial
. Launch in India - tracking the success
Dr. Anthony Beardsworth, Lead Physician, Primary Care
Eli Lilly
14:40 CASE STUDY: Microencapsulated r-FSH - Novel Treatments
for Infertility
. The growing market for the treatment of infertility - tips for market
share
. Learn from the experts - how Serono became market leaders for
the treatment of infertility with Gonal-F
. Gonal-f(R) RFF Pen: the first and only prefilled and ready-to-use
multi-dose FSH in the US
. Benefits of rFSH over urinary products - consistent potency & less
contaminants
. Analysis and updates of recent clinical trials
. Future targets for the treatment of infertility
Dr. Bharat Tewarie, Executive Vice-President, Reproductive Health
Serono
15:20 Afternoon Tea
RECENT ADVANCES IN HYPERTENSION
16:00 CASE STUDY: SPP100 (Aliskiren) - A Novel Treatment for
Hypertension & Related Conditions
. A new mode of action for the treatment of hypertension & end
organ damage
. Analysis of results of recent clinical trials & studies: Aliskiren Vs
Irbesartan
. New technical achievements: producing a commercially viable
manufacturing process
. Possibilites for multiple treatment benefits
Dr. Hans Brunner, Medical Advisor
Speedel
16:40 DISCUSSION: Attendees Perspective
Presentation and discussion of the questionnaire results led by Dr. Ray
Scraggs. This will involve some freeform discussion & the opportunity
to engage in knowledge sharing with fellow professionals.
17:00 Chairman summation and close of conference
Terms & Conditions
NB - Due to high demand, we do not 'reserve' or 'hold' places - a request
for an invoice to be raised will be treated as an official booking and will
be subject to the cancellation policy as outlined below.
Cancellations/substitutions and name changes: All bookings carry a 50%
liability after the booking has been made, by post fax, email or web. There
will be no refunds for cancellations received on or after one month before
the start of the conference (e.g. cancellation on or after 20th January for
a conference starting on 20th February). If you decide to cancel after this
date the full invoice remains payable. Conference notes, which are available
on the day, will be sent to you. Unfortunately we are not able to transfer
places between conferences and executive briefings. However if you are
unable to attend the event you may make a substitution/name change at any
time as long as we are informed in writing by e-mail, fax or post. Name
changes and substitutions must be from the same company and are not
transferable between companies or countries.
Indemnity: visiongain Ltd reserve the right to change the
conference/executive briefing content, timing, speakers or venue without
notice. The event may be postponed or cancelled due to acts of terrorism,
war, extreme weather conditions, industrial action, acts of God or any event
beyond the control of visiongain Ltd. If such a situation arises we will
endeavour to reschedule the event. However, visiongain Ltd cannot be held
responsible for any cost, damage or expenses, which may be incurred by the
customer as a consequence of the event being postponed or cancelled. We
therefore strongly advise all customers to take out insurance to cover the
cost of the registration, travel and expenses.
To unsubscribe please reply with unsubscribe in the subject line.
Data protection: Visiongain Ltd gathers and manages data in accordance with
the Data Protection Act 1998. Information contained about you may be used to
update you on visiongain Ltd products and services via post, telephone, fax
or email, unless you state otherwise. If you wish your details to be
amended, please send your request to the Database Manager, visiongain Ltd,
40 Tooting High Street, London, SW17 0RG. Alternatively please reply with
unsubscribe in the subject line. Please allow approximately 7 days for your
removal or update request, you may receive additional pieces of
communication from visiongain Ltd during the transitional period, whilst the
changes come into effect.
Dear friends,
After our meeting and after having the agreement of my wife, finally I have
decided to accept the proposal of Klaus Brunnstein of chairing the IPC of
WCC 2006.
I wish to thank all of you for your comments in favour and against my
acceptation of this charge.
Best regards
Ramon
=========================================================================
Ramon Puigjaner
Universitat de les Illes Balears
Departament de Ciencies Matematiques i Informatica
07122 PALMA (Spain)
Phone: +34-971173288 Fax: +34-971173003
e-mail: putxi(a)uib.es
=========================================================================
===========================================================================
Asthma Therapies 2004 - Clinical Trials, Novel Treatments and Drug Delivery
15th and 16th December 2004 - Workshop: 14th December 2004
Hilton Kensington Hotel, London
===========================================================================
**** CONFERENCE BROCHURE AVAILABLE - REQUEST YOURS NOW ****
THEMES WILL INCLUDE:
**Learn from the experts: Altana presents on new inhaled corticosteroid,
Ciclesonide
**New information on innovative Drug Roflumilast
**Identify Key Market Trends and Profit from
**Emerging Developments in Asthma Therapeutics
**Future Targets in Asthma Therapeutics - Genetic and Genomic Approaches;
JNK; Chemokine Receptor Antagonists
**Learn how to get your Pipeline drugs to the Market Faster
**How Pharma Companies can make Successful and Lucrative Alliances with Drug
Delivery Companies
**Learn from leading manufacturers, including 3M and Bespak
KEY SPEAKERS
**Dr. Dirk Bredenbroeker, Head, Clinical Research Pulmonology, Altana
**Dr. Noel Snell, Global Clinical, Respiratory Medicine, AstraZeneca
**Dr. James Stefely, Senior Research Specialist, 3M
**Dr. Anthony Coyle, Director, Millennium
**Dr. Kate Blease, Senior Scientist, Celgene
**Dr. Frank Cerasoli, Director of Medical Relations, Altana
**Dr. John Pritchard, Manager, Inhalation Therapy, 3M
**Doug Smalley, Director, Business Development, Vectura
**Dr. Tol Purewal, Head of Research and Development, Bespak Europe Ltd
**Dr. Troels Keldman, Managing Director, Direct Haler
**Richard Turner, Sales Manager, Pharmaceutical Division, Presspart
Manufacturing
**Dr Alan Jones, Director & Academic General Practitioner, Clintrials Wales
-----------------------------------------------------------------
This event will also feature: Pre-conference Interactive Workshop
-----------------------------------------------------------------
+Forcasting the Commercial Potential for Respiratory Products+
Led by: Gary Johnson, Managing Director, Inpharmation
+Working Together to Produce the Next Generation of Asthma Products+
Led by: Phil Seeney, Product and Process Engineering, PA Consultancy
WHO SHOULD ATTEND THIS EVENT:
**Director Respiratory Disease
**Global Clinical Expert Respiratory Medicine
**Senior Distinguished Scientist, Respiratory
**Vice President, Research
**Director, Worldwide Epidemiology
**Executive Director, Respiratory and Allergy
**Head of Clinical Research, Pulmonology
**Vice President, Respiratory Clinical Medicine and Medical Affairs
**Global Director, Respiratory Science
**Associate Director, Product Development
**Head, Asthma Research
**Head, Pharmacology
**President, Signal Research Development
**Executive Vice President Research and Development
**Pharmaceutical Operations Director
**Executive Vice President, Research
---------------------
DELEGATE REGISTRATION
---------------------
Places at this event are strictly limited so BOOK YOUR PLACE NOW.
To make a booking on this event, please contact me via phone or email. Book
early to secure a place.
- PRICING -
Attend the:
2 Day conference with interactive workshop - ONLY GBP1600 plus VAT
2 Day conference - ONLY GBP1299 plus VAT
Workshop only - ONLY GBP650 plus VAT
- BOOKINGS -
Booking is easy, simply contact me on:
Telephone: +44 (0)20 8767 6711
Fax: +44 (0)20 8767 5001
Terms and conditions apply - see below
Email: mailto:andrew.oliver@visongaingroup.com
Please find below the conference agenda. To book your place at simply
give me a quick ring or email me stating whether you require a single place
or a group booking.
I look forward to hearing from you soon.
**** FULL CONFERENCE AGENDA BELOW ****
==================================================
PRE-CONFERENCE WORKSHOP Tuesday 14th December 2004
==================================================
Morning Session:
Forcasting the Commercial Potential for Respiratory Drugs
* Discover the pitfalls of patient based forcasting and learn how to
make accurate forcasts
* Pricing: What allows premium pricing for respiratory products and
how to guage how big the premium can be.
* How the 'big three' factors in market share function for respiratory
products
* Devices: to what extent do the NCE or the device drive commercial
success?
Led by: Gary Johnson, Managing Director, Inpharmation
Afternoon Session:
Working Together to Produce the Next Generation of Asthma Products
* Reacting to turbulent and changing product lifecycles
* Explore the opportunity to rethink traditional development
methods
* Investigate how the product development model will change in
the future
* Learn how your company can influence the product development
approaches of the future
Led by: Phil Seeney, Product and Process Engineering, PA Consulting
Schedule: The workshops will run from 10:00 until 16:30 with lunch and
refreshments at appropriate intervals
=============================
DAY 1 Wednesday 15th December
=============================
09:00 Registration and coffee
09:30 Opening remarks from the Chair
John Pritchard, Manager Inhalation Therapy, 3M
NEW DRUGS IN THE ASTHMA PIPELINE
09:40 OPENING KEYNOTE SPEAKER
Roflumilast - PDE IV inhibitors for asthma and COPD
* How to target PDEIV Inhibitors to develop innovative
asthma therapies
* Update and results of phase III clinical trials
* Role of PDE IV inhibitors in modulating inflammatory cells -how
effective are they?
* How to reduce the side effects
Dr Dirk Bredenbroeker, Head, Clinical Research Pulmonology
Altana
FUTURE TARGETS FOR ASTHMA THERAPIES
10:20 The Development of Effective Strategies for Asthma
Management and Future Impact of New Treatments
* How physicians and patients have responded to growing
morbidity and risk
* Asthma Treatment Guidelines - why aren't they observed?
* The impact of new treatments - fixed combinations
- contribution of leukotrienes
* Concomitant diseases and their implications for asthma
treatment
* The future of the Asthma Market
Graham Lewis, Vice President, Europe Pharma Strategy
IMS Health
11:00 Morning Coffee
11:20 JNK - Controlling Multiple Inflammatory Cytokines:
Focus and SP600125
* Mediators and mechanisms of JNK inhibitors involved in
asthma
* Hyperresponsiveness, lung inflammation and airways
remodelling - how JNK inhibitors affect animal models
* JNK inhibitors or corticosteroids - which is most beneficial to
you?
* CASE STUDY: SP600125 Celgene - results from recent studies
Dr. Kate Blease, Senior Scientist
Celgene
12:00 Antiinflammatory Therapies - Chemokine Receptor
Antagonists: Exploring Future Possibilities
* Chemokines as mediators of inflammation - regulation and
attraction of leukocytes to the inflammed area
* How chemokines interact with their receptors - CCR3 and the
Eotaxins
* Blockade of CCR3 function by small molecules
* Future directions for anti-CCR3/Eotaxin therapies - what is the
potential for your company?
Dr. James Pease, Senior Lecturer
Imperial College
12:40 LUNCH
CLINICAL TRIALS IN ASTHMA
14:00 How to Select Appropriate Clinical Endpoints in Asthma
Studies
* Regulatory requirements for asthma studies - how they affect
your trials
* Secondary endpoints, surrogate endpoints and proof of
principle in asthma trials
* Examples of clinical endpoints - how they can be adapted for
your trials
* Potential endpoints for disease-modifying agents
* Safety Assessments - where you can refine policies
Dr. Noel Snell, Global Clinical Expert, Respiratory Medicine
AstraZeneca
14.40 Challenges in Asthma Research at the Primary Care/
Patient Interface
* Patients perception of Asthma - distancers, deniens &
progmatists.
* The New General Practice Contract - help or hindrance in
asthma research.
* Anti Inflammatory studies - challenges and opportunities
* The appropriateness of clinical end points.
* General practice networks - strengths & weaknesses.
Dr Alan Jones, Director, & Academic General Practitioner
Clintrials Wales
15:20 Afternoon Tea
15:40 How to Treat Co-existing Allergic Rhinitis and Allergic
Asthma
* How to reduce the severity of allergic asthma symptoms by
treatment of co-existing allergic rhinitis
* New ARIA and IPAG guidelines - calls for integrated therapy in
the treatment of allergic rhinitis and asthma
* Initiative from drug delivery - medication systems for
integrated therapy
* The second-generation multiple-route respiratory combination
therapy concept
Dr. Troels Keldman, Managing Director
Direct Haler
16.20 Questions and Discussion
16.30 Summation of day one from conference chair
16.40 Close of Day One
============================
DAY 2 Thursday 16th December
============================
09:00 Registration and Coffee
09:30 Opening remarks from the Chair,
John Pritchard, Manager Inhalation Therapy, 3M
NEW DRUGS IN THE ASTHMA PIPELINE
09:40 OPENING KEYNOTE SPEAKER
CASE STUDY: Ciclesonide - Safety Profile of New
Inhaled Corticosteroids
* What to expect from an ideal inhaled corticosteroid
* Phase III clinical studies - how to ensure safety and efficacy
* Topical and systematic safety - new methods of eliminating
side effects
* HPA axis function - results from pharmacodynamic studies
Dr Frank Cerasoli, Director of Medical Relations
Altana
10:20 Genetic and Genomic Approaches to Understanding
Asthma
* How to identify human genes as future targets for asthma
therapy- the impact of genetics on asthma therapy
* Murine experimental genetic model - how they help in human
asthma
* Speed up your identification of genetic loci - genetic and
genomic technologies
* How to regulate innate and adaptive immune system interface
* Asthma Genetics and the Genetics of other inflammatory
diseases
Dr. Andrea Heinzmann
University of Freiburg
11:00 Morning Coffee
11:20 New Developments in Asthma Therapy - Ventures for
your Company
* Targets in asthma research - past present and future
* Areas for growth: where can your company enter the asthma
market?
* Outlook: new targets for pain relief ligands and the future for
pain therapies in the clinic
* CFCs to HFAs: advice on how best to make the transition to
comply with new guidelines
* What are the new combination drugs dominating the market?
* Regulation changes - how will they affect your pipeline?
Dr. Anthony Coyle, Director
Millennium
THE INCREASING IMPORTANCE OF DRUG DELIVERY SYSTEMS
12:00 Drug Delivery and Pharma Companies - Learn from the
best: Vectura and Skyepharma
* How a successful partnership can benefit your company
* How to select a device development for asthma
medication
* Technical influences on the choice of delivery device for
asthma therapies
Doug Smalley, Director of Business Development
Vectura Group Plc
12:40 Lunch
14:00 pMDI: The Transition from "Safe, Compatible & Stable
Containment" to "Complex and Integral Drug Delivery
Device Component"
* The Evolution, once a safe and stable environment, and now!
* Critical Success Factors - precise and robust
* Performance demands, recent innovations for pMDIs - new
molecules and therapeutic opportunities
* Regulatory requirements - raising the bar
* The Way Ahead - Challenges, Solutions & Opportunities
Richard Turner, Sales Manager, Pharmaceutical Division
Presspart Manufacturing
14:40 Accelerating the Development of Inhaled Drugs
* Obtaining the best balance - how to eliminate
unsuccessful compunds and minimise development time
* How to chose the best delivery system in early trials
* Which is the best approach? - DPIs, MDIs or Nebulisers
* How to meet the regulatory challenges
John Pritchard, Manager of Inhalation Therapy
3M
15:20 Afternoon Tea
15:40 CASE STUDY: Bespak: The MDI Valve Evolution
* Short historical perspective - lessons to be learned from the
past
* Current valves and their performance - how your drugs can
benefit
* Innovative improvements in design - Chamberless valves and
no-prime valves
* Future developments: next generation metered valves with
improved dose consistency
Dr Tol Purewal, Head of Research and Development
Bespak Europe Ltd
16:20 CASE STUDY: Future Benefits from New formulation
approaches: Particle Engineering and New Excipients
* 3M's development of HFA-compatible excipients :
Suspension,solutions and sustained release delivery
* How to improve delivery to the lungs - particle
engineering of drugs and excipients
* HFA propellant system compatibility with protein and
peptide formulations
Dr James Stefely, Senior Research Specialist
3M
17:00 Questions and Discussion
17:20 Chairman summation
17:30 Close of Conference
Terms & Conditions
NB - Due to high demand, we do not 'reserve' or 'hold' places - a request
for an invoice to be raised will be treated as an official booking and will
be subject to the cancellation policy as outlined below.
Cancellations/substitutions and name changes: All bookings carry a 50%
liability after the booking has been made, by post fax, email or web. There
will be no refunds for cancellations received on or after one month before
the start of the conference (e.g. cancellation on or after 20th January for
a conference starting on 20th February). If you decide to cancel after this
date the full invoice remains payable. Conference notes, which are available
on the day, will be sent to you. Unfortunately we are not able to transfer
places between conferences and executive briefings. However if you are
unable to attend the event you may make a substitution/name change at any
time as long as we are informed in writing by e-mail, fax or post. Name
changes and substitutions must be from the same company and are not
transferable between companies or countries.
Indemnity: visiongain Ltd reserve the right to change the
conference/executive briefing content, timing, speakers or venue without
notice. The event may be postponed or cancelled due to acts of terrorism,
war, extreme weather conditions, industrial action, acts of God or any event
beyond the control of visiongain Ltd. If such a situation arises we will
endeavour to reschedule the event. However, visiongain Ltd cannot be held
responsible for any cost, damage or expenses, which may be incurred by the
customer as a consequence of the event being postponed or cancelled. We
therefore strongly advise all customers to take out insurance to cover the
cost of the registration, travel and expenses.
To unsubscribe please reply with unsubscribe in the subject line.
Data protection: Visiongain Ltd gathers and manages data in accordance with
the Data Protection Act 1998. Information contained about you may be used to
update you on visiongain Ltd products and services via post, telephone, fax
or email, unless you state otherwise. If you wish your details to be
amended, please send your request to the Database Manager, visiongain Ltd,
40 Tooting High Street, London, SW17 0RG. Alternatively please reply with
unsubscribe in the subject line. Please allow approximately 7 days for your
removal or update request, you may receive additional pieces of
communication from visiongain Ltd during the transitional period, whilst the
changes come into effect.
**************************************************************
Scanned by VisNetic MailScan for SMTP Servers.
Visit http://www.deerfield.com/products/visnetic_mailscan.
**************************************************************
CALL FOR PAPERS
IFIP Open Conference on
Metropolitan Area Networks
Architecture, protocols, control, and management
HCMC, Viet Nam, April 4-6, 2005
http://phare.lip6.fr/ifip2005/openconf.php
Dear colleague,
Find herein enclosed the announcement of the SCI2005 invited session untitled:
OBJECT-ORIENTED MODELING IN BIOLOGY AND MEDECINE
that will be held in Orlando (USA) on July 10-13 2005
We hope you contribute to the session that will focus on data modeling and data
integration in Systems Biology.
We apologize for multiple copies.
APPLICATION DEADLINE for extended abstracts and papers : December 18th, 2004
The organizers,
Magali ROUX-ROUQUIE, PhD
Informatics Laboratory of Paris 6 (LIP6)
CNRS & University of Pierre and Marie Curie
8, rue du Capitaine Scott 75015 Paris
France
magali.roux(a)lip6.fr
&
W. Jim Zheng, PhD
Biostatistics, Bioinformatics & Epidemiology
Medical University of South Carolina
135, Cannon street suite 303
P.O. Box 250835
Charleston, SC 29425 USA
zhengw(a)musc.edu
To TC6 representative and to the WG chair
This pdf explain the genesis of the IFIP TC6 ConfWork, a tool
developed to help TC6 event organizers as well the present status of
this tool.
The procedure for an TC6 event organizer who want to use this tool is
also detailed in this pdf.
I hope that the WG chair will not forget to forward this pdf to the
organizer of all their events.
BR
Andre Danthine
--
--------------
ANDRE DANTHINE andre.danthine(a)ulg.ac.be
+ 32 4 383 75 42
25, rue Henri Fays
B-4160 Anthisnes (Belgium)
I com el representant d'Andorra no diu res, i com el catala el la meva
llengua materna i tambe es oficial alla on visc, us dic:
Que no tinc res mes per a la reunio que tindrem a Bangkok on deixare un
dels meus carrecs en mans de l'Ana Pont.
I si no ho heu entes pregunteu-li a en Miquel Nicolau!!
Cordialment
Ramon
Otto Spaniol wrote:
> Dear all,
>
> rien ne va plus ... concernant les contributions pour les documents de la
réunion TC6 2004/2 à Bangkok.
>
> Vous pourriez adresser les choses les plus importantes
> (s'il y en aurait cettes choses)
> à Chutiporn Anutariya <chutiporn(a)shinawatra.ac.th>.
>
> Cordialement
> Otto
=========================================================================
Ramon Puigjaner
Universitat de les Illes Balears
Departament de Ciencies Matematiques i Informatica
07122 PALMA (Spain)
Phone: +34-971173288 Fax: +34-971173003
e-mail: putxi(a)uib.es
=========================================================================
Waarom? Pourquoi? Eh?
Ik hoop dat U een prettige vergadering hebben!
Peter
PS Jose - what's that about swimming?
-----Original Message-----
From: André Danthine [mailto:Andre.Danthine@ulg.ac.be]
Sent: 18 November 2004 13:24
To: Otto Spaniol; José Neuman de Souza; Volker Tschammer
Cc: ifip-tc6(a)informatik.rwth-aachen.de
Subject: Re: [ifip-tc6] Rien ne va plus
Otto,
do not forget the frogs
Andre
At 13:19 +0100 18/11/04, Otto Spaniol wrote:
>Dear all,
>
>>J'ai rien compris !!
>>I didn't understand anything !
>>Não entendi NADA !!
>>
>>Neuman.
>>
>>> Ja wenn's ia olle zsamma in eirer eigenen Sproch reds, nacha bring
>>> i mei Bayerisch a ins Spuil.
>>> Griast eich und vuil freid in Bangkok.
>>> Volker
>>>
>It was nice to see that TC6 is really international!
>Of course, the Bavarian language (a German dialect) was most difficult.
>Maybe we can see even more languages ... Bulgarian, Chinese, Japanese,...
>
>I have once produced a dictionary which contains just the sentence
>"Attention please! There is a turkey crossing the street" in more than
>100 languages world-wide. This booklet was (and still is) very useful
>because...
>if a take a taxi in a foreign country then the taxi driver will show me
>the sightseeing highlights and will not take care on the road. And if
>then a turkey wants to cross the road the driver risks to kill the Turkey.
>Thus I have to warn the driver but conventional dictioonaries are not
>very helpful for such a fast warning.
>By using my own dictionary I have saved the lives of more than a dozen
>turkeys already. My second booklet is for hedgehogs instead as of for
turkeys.
>
>Best regards
>Otto
>
>
>
>
>_______________________________________________
>ifip-tc6 mailing list
>ifip-tc6(a)lists.RWTH-Aachen.DE
>http://MailMan.RWTH-Aachen.DE/mailman/listinfo/ifip-tc6
--
--------------
ANDRE DANTHINE andre.danthine(a)ulg.ac.be
+ 32 4 383 75 42
25, rue Henri Fays
B-4160 Anthisnes (Belgium)
_______________________________________________
ifip-tc6 mailing list
ifip-tc6(a)lists.RWTH-Aachen.DE
http://MailMan.RWTH-Aachen.DE/mailman/listinfo/ifip-tc6
This e-mail and any attachment is for authorised use by the intended recipient(s) only. It may contain proprietary material, confidential information and/or be subject to legal privilege. It should not be copied, disclosed to, retained or used by, any other party. If you are not an intended recipient then please promptly delete this e-mail and any attachment and all copies and inform the sender. Thank you.
CALL FOR PAPERS
IEEE International Workshop on Self-Managed Systems & Services (SelfMan 2005)
Nice, France, 19 May 2005
http://madyne.loria.fr/selfman2005/
co-located with IM 2005
http://www.ieee-im.org/
Scope:
As the distributed systems and services that sustain our day-to-day IT and
communication infrastructures become increasingly complex, traditional solutions
to manage and control them seem to have reached their limits. Researchers are thus
testing alternate paradigms to organize and structure them. In recent years,
self-managed systems and services have raised much interest in integrated
management, distributed systems and software engineering. This interest builds on
the success already encountered by self-organized and self-stabilizing systems in
distributed artificial intelligence, material science, thermodynamics, etc.
During this workshop, we wish to gather people with different backgrounds to
analyze and discuss the potential of self-* technologies for managing and
controlling distributed systems and services. Areas of interest include
self-management, self-organization, self-adaptability, self-monitoring,
self-tuning, self-repair and self-configuration. For instance, workshop
contributions could describe success stories in a specific field, while others
could make analogies between several fields, and yet others could propose new
ideas or thought-provoking solutions to old/new problems.
Topics of interest to this workshop include, but are not limited to, the following:
- self-managed distributed systems and networks
- context awareness and self-adaptation
- self-organization in P2P applications
- self-organized MANETs and sensor networks
- self-adaptive systems
- self-repairing distributed systems
- self-configured networks
- self-organized service deployment
- self-adaptive e-business services
- autonomic systems
- goals and policies for self-managed systems
- decision making in self-* systems
The structure of this workshop will encourage discussions and foster future
collaborations. Attendance will be limited to 50 participants. Authors should
submit 4-page position papers to <jp.martin-flatin(a)ieee.org> in PDF format.
Selected papers will be available on the workshop website (no transfer of
copyright).
Co-chairs:
Jean-Philippe Martin-Flatin, University of Quebec in Montreal, Canada
Joe Sventek, University of Glasgow, UK
Kurt Geihs, University of Kassel, Germany
Program Committee:
Ozalp Babaoglu, University of Bologna, Italy
Geoff Coulson, Lancaster University, UK
Giovanna Di Marzo, University of Geneva, Switzerland
Joe Hellerstein, IBM T.J. Watson Research Center, USA
Alexander Keller, IBM T.J. Watson Research Center, USA
Robert Laddaga, Massachusetts Institute of Technology, USA
Gero Muehl, Technical University Berlin, Germany
George Pavlou, University of Surrey, UK
Jerry Rolia, HP Labs Palo Alto, USA
Juergen Schoenwaelder, International University Bremen, Germany
Karsten Schwan, Georgia Institute of Technology, USA
Morris Sloman, Imperial College
Aad van Moorsel, Newcastle University, UK
Robbert van Renesse, Cornell University, USA
Maarten van Steen, Vrije Universiteit Amsterdam, The Netherlands
Ray Welland, University of Glasgow, UK
Important Dates:
Submission deadline: 15 February 2005
Notification of acceptance: 15 March 2005
Final paper due: 15 April 2005
